Condition: Malignant Tumor · Advanced Solid Tumor · Glioblastoma Multiforme · Sponsor: Phost'In Therapeutics
The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.
This description comes directly from the study's public registry record.
Karine Chorro, Mrs. · +33 (0) 4 11 93 77 51 · phast@phostin.com
Always discuss trial participation with your own doctor first.
| Institut du Cancer de Montpellier | Montpellier, France | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Recruiting |
| Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia | Reggio Emilia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05495295